Skip to main content
. 2020 Nov 27;10:574277. doi: 10.3389/fonc.2020.574277

Figure 6.

Figure 6

JWH133 promotes the expression of CYP2J2/11,12-EET of microglia by activating the ERK pathway. (A) Representative western blot images and quantitative data of p-ERK and total ERK of primary microglia in the Control, JWH133, and JWH133 + AM630 treatment groups. Data are presented as mean ± S.E.M, n = 5; **P < 0.01 indicates significant differences vs. Control; ##P < 0.01 indicates significant differences vs. JWH133 treatment (one-way ANOVA followed by Tukey’s post hoc test). (B) Relative CYP2J2 mRNA level (% of Control level) in the Control, JWH133, JWH133 + AM630, and JWH133 + SCH772984 treatment groups. Data are presented as mean ± S.E.M, n = 5; **P < 0.01 indicates significant differences vs. JWH133 treatment (one-way ANOVA followed by Tukey’s post hoc test). (C) 11,12-EET content (ng/ml) in the Control, JWH133, JWH133 + AM630, and JWH133 + SCH772984 treatment groups. Data are presented as mean ± S.E.M, n = 5; **P < 0.01 indicates significant differences vs. JWH133 treatment (one-way ANOVA followed by Tukey’s post hoc test).